Verapamil for Chronic Migraine Prevention
Verapamil is NOT a first-line agent for chronic migraine prevention and should only be considered after failure of proven first-line therapies (propranolol, timolol, amitriptyline, or divalproex sodium), as the evidence for verapamil is poor quality and suggests only modest effect at best. 1
Evidence Quality and Efficacy
The guideline evidence for verapamil in migraine prevention is consistently weak:
- The evidence for verapamil is characterized as "poor quality and difficult to interpret, suggesting only a modest effect" in the 2002 Annals of Internal Medicine systematic review that forms the basis of major headache guidelines 1
- This stands in stark contrast to first-line agents like propranolol and timolol, which have "good evidence for efficacy" 2
- Flunarizine (a different calcium channel blocker, 10 mg/day) has proven efficacy but verapamil specifically does not share this evidence base 1, 3
First-Line Agents to Use Instead
Before considering verapamil, ensure adequate trials of these proven agents 2:
- Propranolol 80-240 mg/day (good evidence, generally well-tolerated) 2, 3
- Timolol 20-30 mg/day (good evidence) 2, 3
- Amitriptyline 30-150 mg/day (good evidence, superior for mixed migraine/tension-type headache) 2, 3
- Divalproex sodium 500-1,500 mg/day (good evidence) 2
An adequate trial means starting low, titrating slowly, and maintaining therapeutic dosing for 2-3 months before declaring treatment failure 2, 1
When Verapamil Might Be Considered
Verapamil may be appropriate only when:
- All first-line agents have failed or are contraindicated 1
- Beta-blockers are contraindicated (e.g., asthma, severe bradycardia, heart block) 2
- Tricyclics are not tolerated (anticholinergic effects, sedation) 2
- Valproate is contraindicated (pregnancy, liver disease) 2
Dosing Protocol (If Used)
Based on limited research evidence 4, 5, 6:
- Start: 240 mg/day in divided doses (80 mg three times daily) 4, 5
- Titrate: Increase to 320 mg/day if inadequate response (320 mg/day was significantly more effective than 240 mg/day in one study) 4
- Maximum: Up to 480 mg/day for migraine prophylaxis 4
- Doses are typically divided three times daily 4, 5
Critical Monitoring Requirements
ECG monitoring is mandatory when using verapamil, particularly at higher doses 7:
- Baseline ECG before starting 7
- Repeat ECG with each dose increase 7
- Monitor for PR interval prolongation (>0.2 seconds indicates first-degree heart block) 7
- In cluster headache patients on verapamil, 19% developed arrhythmias and 36% had bradycardia, with 12% developing first-degree heart block 7
Contraindications
Verapamil should NOT be used in patients with 8:
- Heart failure with reduced ejection fraction (HFrEF) 8
- Atrioventricular block (any degree) 8, 7
- Sick sinus syndrome 8
- Severe bradycardia (HR <50 bpm) 8, 7
- Hypotension 8
- Concurrent use with beta-blockers (increased risk of heart block and bradycardia) 8
Common Adverse Effects
Expect these side effects 1, 8, 1:
- Constipation (most common) 8
- Dizziness 1
- Peripheral edema 1
- Flushing 1
- Headache 8
- Gingival hyperplasia (with chronic use) 8
- Bradycardia 8, 7
Important Clinical Pitfalls
- Do not confuse verapamil's proven efficacy for cluster headache with its weak evidence for migraine - the evidence bases are completely different 9, 7
- Do not skip ECG monitoring - cardiac conduction abnormalities are common and potentially serious 7
- Do not use verapamil as first-line therapy - this violates guideline recommendations that prioritize agents with good evidence 2, 1
- Ensure the patient truly has chronic migraine (≥15 headache days/month) before any preventive therapy, as this determines whether preventive treatment is indicated 10
Superior Alternative: OnabotulinumToxinA
For patients who have failed multiple oral preventives, onabotulinumToxinA (Botox) has substantially stronger evidence than verapamil for chronic migraine prevention 10: